RELATED CONTENT
NEWS
- Biogen claims oral MS drug BG-12 could outperform Gilenya
- Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
- Seattle Genetics investors retreat on robust Adcetris pricing
- Biogen/Elan hope updated Tysabri label will lend confidence to patients/prescribers
COMMENT
Other Informa Comment
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

